Tokyo, Aug. 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062648) titled 'Phase I/II study evaluating the safety, tolerability, and efficacy of sacituzumab govitecan in combination with pegfilgrastim in patients with HER2-negative breast cancer' on Aug. 21.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Rakuwakai Otowa Hospital
Condition:
Condition - Unresectable or recurrent HER2-negative breast cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The purpose of this clinical trial is to evalu...